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Abstract: A series of 4 -[4 -(1-(aryl)ureido)benzamide]podophyllotoxin congeners (11a–
l) were synthesized and evaluated for their cytotoxic activity against six human cancer 
cell lines. Some of the compounds like 11a, 11h, 11k and 11l showed significant anti-
proliferative activity in Colo-205 cells and were superior to etoposide. The flow-
cytometric analysis studies indicated that these compounds show strong G1 cell cycle 
arrest, as well exhibited improved inhibitory activities on DNA topoisomerase I and II  
enzymes. These compounds induce apoptosis by up regulating caspase-3 protein as 
observed by ELISA and Western blotting analysis. In addition, a brief structure–activity 
relationship studies within the series along with docking results of representative 
compounds 11a, 11h, 11k, 11l were presented. 
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1. Introduction 
 
( )-Podophyllotoxin (1) is a lignan of aryltetralin family found in the plants like 
Podophyllum peltatum and Podophyllum emodi.1 Interest in podophyllotoxin has been 
heightened by its potent antimitotic activity2,3 and it inhibits the assembly of tubulin 
protein into microtubules through tubulin binding at the colchicine site.4,5  However, it 
failed to advance in human clinical trials because of toxic side-effects. Extensive 
structural modifications have been performed since 1950s, principally at Sandoz 
Laboratories,6,7 which led to the semi-synthetic derivatives, etoposide (2)8 and teniposide 
(3, Figure 1).9,10 Both these derivatives demonstrated significant activity with lower 
toxicity in clinical trials and they target DNA topoisomerase-II .11 These are currently 
being used as frontline cancer chemotherapeutics against various cancers, including 
small-cell lung cancer, testicular carcinoma, lymphoma, and Kaposi’s sarcoma.12 
However, their therapeutic use has encountered certain limitations such as acquired drug 
resistance, and lower bioavailability. To overcome such problems, extensive synthetic 
efforts have been carried out by a number of researchers. This led to the development of 
NK-611 (4) and GL-331 (5), which are in different stages of clinical studies and exhibit 
improved cytotoxicity as well as DNA topoisomerase-II  inhibition.13 It has also been 
indicated in the literature that bulky substitution at the C-4 position of the 
podophyllotoxin usually enhances the cytotoxicity and DNA topoisomerase-II  inhibition 
activity.14-19  
Similarly, the urea derivatives such as bis-aryl ureas have been most extensively 
investigated new chemical entities following the success of Sorafenib20 for the treatment 
of advanced renal cell carcinoma and unresectable hepatocellular carcinoma.21,22 More 
importantly, this class of urea derivatives have been found to be potent inhibitors of 
human DNA topoisomerase-I and II .23-25  
DNA topoisomerase-I and topoisomerase-IIα enzymes are expressed at different 
levels in different cell types; the expression of topoisomerase-I is prominent in colon 
cancer cell lines, while topoisomerase-II is high in breast and ovarian cancer cell lines.26 
The expression of either of the enzyme, sufficient to support cell division and the 
development of resistance to topoisomerase-I inhibitors is often accompanied by a 
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concomitant rise in the level of topoisomearse-IIα and vice versa.27,28 Thus dual inhibitors 
of topoisomerase-I and topoisomerase-IIα may have advantages and there has been much 
interest in such compounds in clinical evaluation, including intoplicine and XR 
500016.29,30 
In our ongoing research efforts to design and develop new potent anticancer agents, 
we have been involved for many years in the synthesis and in vitro biological evaluation 
of podophyllotoxin congeners.31-37 In continuation of these efforts, we have undertaken 
the synthesis of some new analogues of podophyllotoxin by linking it to a urea moiety 
through an aryl amino spacer at C-4 position of the podophyllotoxin scaffold with a view 
to combine the pharmacological characteristics of both these chromophores. In the 
present study, we report the synthesis and in vitro cytotoxic activity of a series of novel 
4β-[4 -(1-(aryl)ureido)benzamide]podophyllotoxin derivatives (11a–l). Most of these 
podophyllotoxin derivatives have exhibited better cytotoxicity than etoposide. Based on 
their promising in vitro cytotoxicity, it was considered of interest to investigate their role 
in the cell proliferation apart from their effect on DNA topoisomerase-I and II  inhibition. 
  
<Insert Figure 1> 
 
2. Results and Discussion 
2.1. Chemistry 
The new 4β-[4 -(1-(aryl)ureido)benzamide]podophyllotoxin congeners (11a–l) have been 
synthesized from the key intermediate (5R,5aR,8aS,9S)-9-amino-5-(3,4,5-
trimethoxyphenyl)-5,5a,6,8,8a,9-hexahydro[1,3]dioxolo[4',5':4,5]benzo[f]isobenzofuran-
6-one (7)31,32 as depicted in Scheme 1. The compound 7 was coupled with 4-nitrobenzoyl 
chloride (8) in the presence of Et3N to afford 9, which upon nitro reduction with Pd/C 
provides the corresponding amine 10. Finally, this intermediate was then reacted with a 
variety of substituted phenyl isocyanates gave the desired 4β-[4 -(1-
(aryl)ureido)benzamide]podophyllotoxins (11a–l) in overall good yields. 
<Insert Scheme 1> 
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3. Biological activity evaluation 
3.1. Anti-proliferative activity 
All the compounds 11a–l were evaluated for their anti-proliferative activity in 
selected human cancer cell lines of breast, oral, colon, lung and ovarian origin by using 
sulforhodamine B (SRB) method.38 The compounds that exhibit GI50   10−5 M are 
considered to be active in the respective cell lines and the results are illustrated in Table 
1. All the compounds 11a–l exhibit significant anti-proliferative activity with GI50 values 
ranging from 0.01 to 2.90 µM, while the positive controls, etoposide and adriamycin 
demonstrated the GI50 in the range of 0.13 to 3.11 µM and 0.10 to 7.25 µM, respectively. 
Based on the cytotoxicity data, the structure activity relationship (SAR) was examined 
for these new podophyllotoxin congeners (11a–l). It is interesting to observe that one of 
the compounds 11a with chloro substitution at para-position of the phenyl ring showed 
similar or slightly reduced activity in comparison to the methoxy substitution 11h. Both 
these compounds 11a and 11h displayed potent cytotoxic activity against different cell 
lines such as colon, breast and lung cancer cell lines, which were similar or better than 
etopside. However, shifting the chloro group from para-position (11a) to the meta-
position (11b) remarkably decreased the cytotoxicity, suggesting that the electron 
distribution pattern on benzoyl urea side chains probably play an important role towards 
the activity profile. Moreover, the presence of different disubstitutions on phenyl ring 
such as 2,6-dichloro (11c), 3,5-dimethyl (11f), 3,5-ditrifluoromethyl (11g) and 3-flouro - 
4-chloro (11e) groups at different positions of the phenyl ring determined a marked 
decrease or no inhibitory activity on these cancer cell lines. In addition, the introduction 
of heterocyclic motifs into urea side chain, such as furan (11d) and thiophene (11j) 
exhibited marginal or no activity against the different human tumor cell lines, while 11d 
showed selective activity towards MCF7 and DWD cell lines. It is also observed that the 
removal of the phenyl ring and substitution with aliphatic side chains like 2-chloro ethyl 
(11k) and 2-bromo ethyl (11l) derivatives resulted in enhancement of activity and is 
comparable to that of etoposide. Interestingly, all the synthesized compounds 11a–l 
showed potent cytotoxic activity against MCF7 cell lines. The significant growth 
inhibitory activity exhibited by promising compounds like 11a, 11h, 11k and 11l 
prompted us to evaluate their cell viability in Colo-205 cells and MDA-MB-231 cells, 
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with a view to study their detailed biological effects. Both these Colo-205 as well as 
MDA-MB-231 cells were treated with some of these compounds like 11a, 11h, 11k, 11l 
and etoposide at 0.5, 1, 2 and 4 µM concentrations for 24 h. It was observed that below 
0.5 or 1 µM concentrations, there was no significant cytotoxicity; however at 
concentrations 2 or 4 µM, these compounds have exhibited effective cytotoxicity in Colo-
205 and MDA-MB-231 cells as shown in Figure 2A. It was also observed that Colo-205 
cells responded better than MDA-MB-231 cells. Thus, further studies were carried out by 
employing Colo-205 cells at 2 µM concentration. Moreover, trypan blue and ATP 
assays39 clearly indicated that the effect of these podophyllotoxins on the cell viability 
(Figure 2B and 2C). 
 
<Insert Table 1> 
<Insert Figure 2A> 
<Insert Figure 2B> 
<Insert Figure 2C> 
3.2. Effect on cell cycle 
In order to understand the role of these new podophyllotoxin conjugates 11a, 11h, 
11k and 11l, on cell cycle regulation, flow-cytometric analysis was conducted in colon 
cancer cells (Colo-205) at 2 µM concentration for 24 h. It was observed that Colo-205 
cells showed 78%, 76%, 76% and 72% of G1 phase cell cycle arrest in cells treated with 
11a, 11h, 11k and 11l respectively, whereas control (untreated cells) exhibited 65%. 
However, standard drug showed G2/M phase cell cycle arrest (Figure 3). Interestingly, 
DNA topoisomerase-II inhibitors were also known to cause G1 cell cycle arrest.40 
 
<Insert Figure 3> 
 
3.3. Effect on DNA topoisomerase enzyme 
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The DNA topoisomerase-II  enzyme inhibition assay was examined in comparison to 
etoposide. The pBR322 plasmid was incubated with DNA topoisomerase-IIα enzyme that 
causes relaxed DNA. The effect of these compounds 11a–l on topoisomerase-IIα was 
compared with etoposide as standard topoisomerase II  inhibitor at 2 µM concentration as 
shown in Figure 4A. These results were clearly demonstrated that these new compounds 
in particular 11a, 11h, 11k, 11l displayed significant inhibitory activity on 
topoisomerase-II . Further, we have also tested these compounds for inhibitory activity on 
DNA topoisomerase-I. To our surprise, 11a exhibits topo-I inhibition and is comparable 
with respect to camptothecin (CPT), a standard topoisomerase-I inhibitor (Figure 4B). 
Thus, 11a causes significant inhibition of both topoisomerase-I as well as topoisomerase-
II  enzymes. 
 
<Insert Figure 4A and 4B> 
3.4. Effect on caspase-3 
Caspases belong to cysteine protease family and plays a crucial role in the induction 
of apoptosis.41 Previous studies have reported that etoposide, a DNA topoisomerase-II  
inhibitor causes apoptosis by elevating the levels of caspase-3 protein.42 These aspects 
were examined by treating the compounds 11a, 11h, 11k and 11l with Colo-205 cells at 2 
µM concentration for 24 h and compared with etoposide. The lysates obtained were 
subjected to caspase-3 based ELISA and Western blot analysis. It was observed that 
caspase-3 was up-regulated with compound treated cells particularly in case of 11a as 
well as etoposide. The order of performance with regard to caspase-3 activation is 
11a>etoposide>11h>11k>11l as shown in Figure 5A, and 5B. 
 
<Insert Figure 5A and 5B> 
 
It was considered of interest to examine DNA fragmentation and morphological 
changes associated with apoptosis as caspase-3 is known to be responsible for causing 
apoptosis.43,44 Colo-205 cells were treated with 11a (most potent compound) and 
etoposide (Eto) at 2 and 4 µM concentrations for 24 h, and nuclear staining was 
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performed by using Hoechst stain. It was observed that the compound treated cells 
showed DNA fragmentation and blebbing, whereas control cells did not show such 
blebbing, thereby revealing that these compounds induce apoptosis as shown in Figure 6. 
<Insert Figure 6> 
4.0 Molecular docking studies 
To evaluate the binding modes and nature of interactions for some of these potent 
compounds like 11a, 11h, 11k, and 11l with active site residues of human DNA 
topoisomerase I as well as topoisomerase IIα, docking studies were performed by using 
Chemical Computing Group’s Molecular Operating Environment (MOE) software 
2008.10 versions. Human topoisomerase-I (1SC7) and topoisomerase-IIα (1ZXN) 
proteins were retrieved from PDB and refined with protonation, addition of gasteiger 
partial charges and finally energy minimized to relieve bad crystallographic contacts. 
“Active site finder” function of the MOE is used to denote potential docking pockets 
within the protein crystal structure. These compounds 11a, 11h, 11k and 11l were placed 
in the active site pocket of the protein by the “Triangle Matcher” method, which generate 
poses by aligning the ligand triplet of atoms with the triplet of alpha spheres in cavities of 
tight atomic packing. Dock scoring was carried with London dG method and then finally 
retaining their 10 best poses of scoring. The preparation of the ligands for docking 
simulation involves the energy minimization with Molecular Mechanics Force-field 
MMFF94x (Merck Molecular Force Field 94×) and then molecules were subjected to 
conformational search in MOE using the conformational stochastic search module to find 
the lowest energy conformers. To validate the docking accuracy of the program, 
camptothecin and etoposide were considered as standards for the docking in human 
topoisomerase-I and topoisomerase-IIα enzymes, respectively.45, 46 
        Molecular docking of these compounds 11a, 11h, 11k, and 11l showed similar 
interactions and orientations with active site residues in the binding pocket of topo-IIα 
(Figure 7A,7B), and is in correlation with DNA topoisomerase-IIα inhibition assay. 
Methoxy substituents on the trimethoxy phenyl ring of these compounds show common π 
interactions with magnesium and hydrogen-bonding with Asn91 residue similar to 
etoposide in the active site. Common arene-cation interactions were also observed with 
Arg98 residues which are considered to assist in DNA intercalation. Compound 11a 
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shows interaction with adenine moiety, A113 and π-π stacking interaction between 
trimethoxy phenyl moiety of 11a and TGP11 in human DNA topoisomerase-I (Figure 
7C), confirming its dual affinity towards both topoisomerase-I and topoisomerase-IIα 
enzymes. 
 
<Insert Figure 7A> 
<Insert Figure 7B> 
<Insert Figure 7C> 
 
5. Conclusion 
In conclusion, a series of new 4 -[4 -(1-(aryl)ureido)benzamide]podophyllotoxin 
congeners were synthesized and evaluated for their in vitro cytotoxicity, moreover 
detailed studies relating to their biological implications were carried out. Some of the 
compounds 11a, 11h, 11k and 11l showed significant anti-proliferative activity in Colo-
205 cells, and equipotent to that of etoposide. These compounds were tested for their 
effect on cell viability in Colo-205 and MDA-MB-231 cells. The flow cytometric 
analysis indicated that these compounds showed strong G1 cell cycle arrest. It was also 
observed that caspase-3 was up-regulated by these compounds, particularly 11a being the 
most effective among the series. Interestingly, 11a showed dual inhibition of DNA 
topoisomerase I and topoisomerase IIα enzymes. The docking results showed similar 
orientation and interactions at DNA topo-I and topo-IIα active sites compared with 
standards, camptothecin (CPT) and etoposide (Eto) respectively. Overall, these new 
findings provide an insight for future direction of drug design and development of such 
congeners of podophyllotoxin.  
6. Experimental Section 
All chemicals and reagents were obtained from Aldrich (Sigma–Aldrich, St. Louis, 
MO, USA), Lancaster (Alfa Aesar, Johnson Matthey Company, Ward Hill, MA, USA) 
and were used without further purification. Reactions were monitored by TLC, performed 
on silica gel glass plates containing 60 F-254, and visualization on TLC was achieved by 
UV light or iodine indicator. 1H and 13C NMR spectra were recorded on INOVA (400 
MHz) or Gemini Varian-VXR-unity (200 MHz) or Bruker UXNMR/XWIN-NMR (300 
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MHz) instruments. Chemical shifts (δ) are reported in ppm downfield from internal TMS 
standard. ESI spectra were recorded on Micro mass, Quattro LC using ESI+ software with 
capillary voltage 3.98 kV and ESI mode positive ion trap detector. Melting points were 
determined with an Electrothermal melting point apparatus, and are uncorrected. 
6.1.N1-((5S,5aS,8aR,9R)-8-oxo-9-(3,4,5-trimethoxyphenyl)-5,5a,6,8,8a,9-hexahydro 
[1,3]dioxolo[4',5':4,5]benzo[f]isobenzofuran-5-yl)-4-nitrobenzamide (9): To a 
solution containing (5R,5aR,8aS,9S)-9-amino-5-(3,4,5-trimethoxyphenyl)-5,5a,6,8,8a,9-
hexahydro[1,3]dioxolo[4',5':4,5]benzo[f]isobenzofuran-6-one (7, 2.0 g, 0.820 mmol), 
Et3N (2.3 mL, 1.652 mmol) in 20 mL of CH2Cl2 and 4-nitrobenzoyl chloride (8, 1.83 g, 
0.991 mmol) in 10 mL of CH2Cl2 was added under nitrogen atmosphere and stirred at 
room temperature for 3 h, till the completion of the reaction as monitored by TLC. The 
reaction mixture was washed with water and extracted with CH2Cl2, dried over 
anhydrous Na2SO4 and the crude product was purified by column chromatography with 
ethyl acetate/hexane (3:7) provided pure compound 9 in good yield (2.5 g, 92 ). Mp: 174–
177 oC; 1H NMR (200 MHz, CDCl3):   2.95–3.01 (m, 2H), 3.65 (s, 3H), 3.70 (s, 6H), 3.81 
(t, 1H), 4.06–4.13 (dd, 1H, J = 7.5, 6.7 Hz), 4.37– 4.46 (m, 2H), 5.98 (d, 2H, J = 4.5 Hz), 
6.22 (s, 2H), 6.45 (s, 1H), 6.83 (s, 1H), 7.94 (d, 2H, J = 9.0 Hz), 8.14 (d, 2H, J = 9.0 Hz). 
MS (ESI): m/z 563 [M+H]+. 
 6.2.N1-((5S,5aS,8aR,9R)-8-oxo-9-(3,4,5-trimethoxyphenyl)-5,5a,6,8,8a,9-hexahydro 
[1,3]dioxolo[4',5':4,5]benzo[f]isobenzofuran-5-yl)-4-aminobenzamide (10): To a 
solution of N1-((5S,5aS,8aR,9R)-8-oxo-9-(3,4,5-trimethoxyphenyl)-5,5a,6,8,8a,9-
hexahydro[1,3]dioxolo[4',5':4,5]benzo[f]isobenzofuran-5-yl)-4-nitrobenzamide (9, 1.54 g, 
3.53 mmol) in 80 mL of EtOAc was added 300 mg, of 10% Pd/C. The mixture was 
stirred overnight under hydrogen atmosphere, the reaction mixture was filtered and then 
filtrate was evaporated. The crude product was purified by column chromatography with 
ethyl acetate/hexane (6:4) gave pure compound 10 in excellent yield (1.42 g, 98 ). 1H 
NMR (200 MHz, CDCl3):   2.93–3.01 (m, 2H), 3.60 (s, 3H), 3.69 (s, 6H), 3.80 (t, 1H), 
4.01–4.10 (dd, 1H, J = 7.5, 6.7 Hz), 4.30– 4.44 (m, 2H), 6.00 (d, 2H, J = 4.5 Hz), 6.23 (s, 
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2H), 6.43 (s, 1H), 6.80 (s, 1H), 7.90 (d, 2H, J = 9.0 Hz), 8.16 (d, 2H, J = 9.0 Hz). MS 
(ESI): m/z 533 [M+H]+. 
 6.3.N1-((5S,5aS,8aR,9R)-8-oxo-9-(3,4,5-trimethoxyphenyl)-5,5a,6,8,8a,9-hexahydro 
[1,3]dioxolo[4',5':4,5]benzo[f]isobenzofuran-5-yl)-4-(((4-chloroanilino)carbonyl) 
amino)benzamide (11a): To a solution of N1-((5S,5aS,8aR,9R)-8-oxo-9-(3,4,5-
trimethoxyphenyl)-5,5a,6,8,8a,9-hexahydro[1,3]dioxolo [4',5':4,5]benzo[f]isobenzofuran-
5-yl)-4-aminobenzamide (10, 200 mg, 0.37 mmol) in dry CH2Cl2 (10 mL), 4-
chlorophenyl isocyanate (a, 0.81 mL, 0.56 mmol) was added at 0 oC and the stirring was 
continued for 1 h at room temperature. Later, the formed solid was filtered and washed 
thoroughly with CH2Cl2 to afford the pure compound 11a (220 mg, 81%). Mp: 180–183 
oC; [α]D25 = – 45.9 (c = 0.5 in CHCl3); 1H NMR (300 MHz, CDCl3):   3.00 3.10 (m, 2H), 
3.67 (s, 3H), 3.70 (s, 6H), 4.40–4.48 (m, 2H), 4.60 (d, 1H, J = 4.83 Hz), 5.50–5.53 (m, 
1H), 6.01 (d, 2H, J = 6.44 Hz), 6.30 (s, 2H), 6.60 (s, 1H), 6.80 (s, 1H), 7.31 (d, 2H, J = 
8.05 Hz), 7.50 (d, 2H, J = 8.05 Hz), 7.91 (d, 2H, J = 8.19 Hz), 8.60 (d, 2H, J = 8.19 Hz). 
13C NMR (75 MHz, CDCl3):   40.7, 43.0, 47.5, 55.4, 59.8, 68.6, 100.9, 107.7, 108.5, 
109.2, 116.3, 116.9, 123.7, 124.0, 126.1, 127.9, 129.7, 129.9, 130.5, 131.8, 134.8, 134.3, 
137.4, 137.9, 142.3, 146.5, 151.7, 152.3, 166.6, 174.4. MS (ESI): m/z 709 [M+Na]+. 
6.4. N1-((5S,5aS,8aR,9R)-8-oxo-9-(3,4,5-trimethoxyphenyl)-5,5a,6,8,8a,9-hexahydro 
[1,3]dioxolo[4',5':4,5]benzo[f]isobenzofuran-5-yl)-4-(((3-chloroanilino) carbonyl) 
amino)benzamide (11b): To a solution of N1-((5S,5aS,8aR,9R)-8-oxo-9-(3,4,5-
trimethoxyphenyl)-5,5a,6,8,8a,9-hexahydro[1,3]dioxolo [4',5':4,5]benzo[f]isobenzofuran-
5-yl)-4-aminobenzamide (10, 200 mg, 0.37 mmol) in dry CH2Cl2 (10 mL), 3-
chlorophenyl isocyanate (b, 0.8 mL, 0.56 mmol) was added at 0 oC and the stirring was 
continued for 1 h at the room temperature. Later, the formed solid was filtered and 
washed thoroughly with CH2Cl2 to obtain the pure compound 11b (210 mg, 76%). Mp: 
247–249 oC; [α]D25 = – 61.1 (c = 0.5 in CHCl3); 1H NMR (400 MHz, CDCl3):   3.40–3.51 
(m, 2H), 3.73 (s, 3H), 3.77 (s, 6H), 4.41 (t, 1H, J = 8.08 Hz), 4.61–4.69 (m, 2H), 5.49–
5.53 (m, 1H), 6.01 (d, 2H, J = 6.6 Hz), 6.30 (s, 2H), 6.51 (s, 1H), 6.80 (s, 1H), 7.20 (d, 
2H, J = 6.61 Hz), 7.51 (d, 2H, J = 8.08 Hz), 7.70 (s, 1H), 7.91 (d, 2H, J = 8.81 Hz) 8.41 
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(d, 1H, J = 8.08 Hz). 13C NMR (75 MHz, CDCl3):    40.6, 43.1, 47.1, 55.4, 59.8, 68.1, 
100.1, 107.5, 108.7, 109.2, 116.1, 116.7, 120.6, 122.9, 124.0 , 125.0, 125.7, 128.2, 129.1, 
130.8,  131.7, 134.9, 134.6, 137.7, 137.4,  137.9, 142.5, 146.6, 151.9, 152.2, 166.4, 174.3. 
MS (ESI): m/z 686 [M+H]+. 
 6.5.N1-((5S,5aS,8aR,9R)-8-oxo-9-(3,4,5-trimethoxyphenyl)-5,5a,6,8,8a,9-hexahydro 
[1,3]dioxolo[4',5':4,5]benzo[f]isobenzofuran-5-yl)-4-(((2,6-dichloroanilino)carbonyl) 
amino)benzamide (11c): To a solution of N1-((5S,5aS,8aR,9R)-8-oxo-9-(3,4,5-
trimethoxyphenyl)-5,5a,6,8,8a,9-hexahydro[1,3]dioxolo [4',5':4,5]benzo[f]isobenzofuran-
5-yl)-4-aminobenzamide (10), (200 mg, 0.37 mmol) in dry CH2Cl2 (10 mL), 2,6-
dichlorophenyl-1-isocyanate (c), (106 mg, 0.56 mmol) was added at 0 oC and the stirring 
was continued for 1 h at the room temperature. After 1 h, the formed solid was filtered 
and washed with CH2Cl2 thoroughly to obtain pure compound 11c in 190 mg, 80% yield. 
Mp: 140–143 oC; [α]D25 = – 70.6 (c = 0.5 in CHCl3); 1H NMR (300 MHz, CDCl3):   3.20–
3.27 (m, 2H), 3.78 (s, 3H), 3.81 (s, 6H), 4.50–4.57 (m, 1H), 4.71–4.46 (m, 2H), 5.60–
5.65 (m, 1H), 6.10 (s, 2H, J = 2.93 Hz), 6.40 (s, 2H), 6.71 (s, 1H), 7.01 (s, 1H), 7.40 (t, 
1H, J = 7.34, 8.81 Hz), 8.00 (d, 2H, J = 8.81 Hz). 13C NMR (75 MHz, CDCl3):   40.8, 
43.1, 47.2, 55.3, 60.1, 68.6, 100.9, 107.4, 108.6, 109.3, 116.2, 116.9, 123.9, 126.3, 127.8, 
128.0, 129.2, 130.6, 131.4, 132.4, 134.6, 137.4, 137.9, 142.5, 146.9, 151.9, 152.4, 166.7, 
174.3. MS (ESI): m/z 720 [M+H]+. 
 6.6.N1-((5S,5aS,8aR,9R)-8-oxo-9-(3,4,5-trimethoxyphenyl)-5,5a,6,8,8a,9-hexahydro 
[1,3]dioxolo[4',5':4,5]benzo[f]isobenzofuran-5-yl)-4-((((5-bromo-2-thienyl)amino) 
carbonyl)amino)benzamide (11d): To a solution of N1-((5S,5aS,8aR,9R)-8-oxo-9-
(3,4,5-trimethoxyphenyl)-5,5a,6,8,8a,9-hexahydro[1,3]dioxolo[4',5':4,5]benzo[f]isobenzo 
furan-5-yl)-4-aminobenzamide (10), (200 mg, 0.37 mmol) in dry CH2Cl2 (10 mL), 5-
bromothiophenyl isocyanate (d), (76.5 mg, 0.37 mmol) was added at 0 oC and the stirring 
was continued for 1 h at  room temperature. After 1 h, the formed solid was filtered and 
washed with CH2Cl2 thoroughly to obtain the pure compound 11d in 210 mg, 75% yield. 
Mp: 168–170 oC; [α]D25 = – 80.9 (c = 0.5 in CHCl3); 1H NMR (200 MHz, CDCl3):   3.03–
3.17 (m, 1H), 3.50–3.60 (m, 1H), 3.68 (s, 3H), 3.73 (s, 6H), 4.40 (t, 1H, J = 8.81, 7.34 
Hz), 4.61–4.68 (m, 2H), 5.48–5.54 (m, 1H), 6.03 (d, 2H, J = 2.94 Hz), 6.37 (s, 2H), 6.61 
(s, 1H), 6.88 (s, 1H), 7.49–7.58 (m, 4H), 7.93 (d, 2H, J = 8.81 Hz). 13C NMR (75 MHz, 
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CDCl3):   41.0, 43.6, 47.4, 55.8, 60.6, 68.9, 101.0, 107.7, 108.6, 109.2, 116.4, 117.0, 
119.3, 124.0, 124.1, 126.0, 128.3, 129.7, 131.9, 132.5, 135.0, 135.7, 137.6, 137.8, 142.5, 
146.4, 151.7, 152.3, 166.0, 174.2. MS (ESI): m/z 759 [M+Na]+. 
 6.7.N1-((5S,5aS,8aR,9R)-8-oxo-9-(3,4,5-trimethoxyphenyl)-5,5a,6,8,8a,9-hexahydro 
[1,3]dioxolo[4',5':4,5]benzo[f]isobenzofuran-5-yl)-4-(((3-chloro-4-fluoroanilino) 
carbonyl)amino)benzamide (11e): To a solution of N1-((5S,5aS,8aR,9R)-8-oxo-9-
(3,4,5-trimethoxyphenyl)-5,5a,6,8,8a,9-hexahydro[1,3]dioxolo[4',5':4,5]benzo[f] 
isobenzofuran-5-yl)-4-aminobenzamide (10), (200 mg, 0.37 mmol) in dry CH2Cl2 (10 
mL), 3-chloro-4-fluorophenyl isocyanate (e), (63 mg, 0.37 mmol) was added at 0 oC and 
the stirring was continued for 1 h at  room temperature. After 1 h, the formed solid was 
filtered and washed with CH2Cl2 thoroughly obtained the pure compound 11e in 220 mg, 
83% yield. Mp: 180–182 oC; [α]D25 = – 57.9 (c = 0.5 in CHCl3); 1H NMR (200 MHz, 
CDCl3):   2.97–3.14 (m, 1H), 3.48–3.55 (m, 1H), 3.63 (s, 3H), 3.67 (s, 6H), 4.33–4.39 
(m, 1H), 4.49–4.59 (m, 2H), 5.45–5.48 (m, 1H), 6.01 (s, 2H), 6.33 (s, 2H), 6.58 (s, 1H), 
6.85 (s, 1H), 7.33 (d, 2H, J = 5.28 Hz), 7.54 (d, 1H, J = 6.79 Hz), 7.80–7.88 (m, 3H), 
8.61 (d, 1H, J = 6.79 Hz). 13C NMR (75 MHz, CDCl3):   40.7, 43.0, 47.2, 55.6, 60.2, 
68.5, 100.9, 107.4, 108.8, 109.3, 116.5, 116.9, 118.5, 121.9, 122.1, 124.1, 123.9, 126.2, 
128.3, 129.5, 131.5, 133.4, 134.8, 137.7, 137.9, 142.8, 146.9, 152.0, 152.3, 159.1, 166.1, 
174.2. MS (ESI): m/z 727 [M+Na]+. 
 6.8.N1-((5S,5aS,8aR,9R)-8-oxo-9-(3,4,5-trimethoxyphenyl)-5,5a,6,8,8a,9-hexahydro 
[1,3]dioxolo[4',5':4,5]benzo[f]isobenzofuran-5-yl)-4-(((3,5-dimethylanilino)carbonyl 
)amino)benzamide (11f): To a solution of N1-((5S,5aS,8aR,9R)-8-oxo-9-(3,4,5-
trimethoxyphenyl)-5,5a,6,8,8a,9-hexahydro[1,3]dioxolo [4',5':4,5]benzo[f]isobenzofuran-
5-yl)-4-aminobenzamide (10), (200 mg, 0.37 mmol) in dry CH2Cl2 (10 mL), 3,5-
dimethyl-phenyl isocyanate (f), (0.66 mL, 0.56 mmol) was added at 0 oC and the stirring 
was continued for 1 h at  room temperature. After 1 h, the formed solid was filtered and 
washed with CH2Cl2 thoroughly to obtain the pure compound 11f in 200 mg, 86% yield. 
Mp: 176–179 oC; [α]D25 = – 69.9 (c = 0.5 in CHCl3); 1H NMR (200 MHz, CDCl3):   2.50 
(s, 6H), 3.19–3.26 (m, 2H), 3.67 (s, 3H, -OCH3), 3.70 (s, 6H), 4.40 (t, 1H, J = 7.77, 8.32 
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Hz), 4.60–4.68 (m, 1H), 5.51–5.59 (m, 1H), 6.00 (d, 2H, J = 4.90 Hz), 6.30 (s, 2H), 6.61 
(s, 1H), 6.80 (s, 1H), 7.20 (d, 2H, J = 3.96 Hz), 7.50 (d, 2H, J = 8.68 Hz), 7.80 (d, 2H, J = 
8.68 Hz), 8.50 (s, 1H). 13C NMR (75 MHz, CDCl3):    20.7, 40.8, 43.2, 47.3, 55.5, 60.0, 
68.4, 100.8, 107.5, 108.7, 109.1, 116.0, 116.8, 123.8, 125.9, 128.0, 129.3, 131.6, 134.7, 
137.8, 138.2, 142.6, 146.7, 147.3, 151.8, 152.2, 166.5, 174.3. MS (ESI): m/z 703 
[M+Na]+. 
6.9.N1-((5S,5aS,8aR,9R)-8-oxo-9-(3,4,5-trimethoxyphenyl)-5,5a,6,8,8a,9-hexahydro 
[1,3]dioxolo[4',5':4,5]benzo[f]isobenzofuran-5-yl)-4-(((3,5-di(trifluoromethyl) 
anilino)carbonyl)amino)benzamide (11g): To a solution of N1-((5S,5aS,8aR,9R)-8-oxo-
9-(3,4,5-trimethoxyphenyl)-5,5a,6,8,8a,9-hexahydro[1,3]dioxolo[4',5':4,5]benzo[f] 
isobenzofuran-5-yl)-4-aminobenzamide (10), (200 mg, 0.37 mmol) in dry CH2Cl2 (10 
mL), 3,5-bis(trifluoromethyl)phenyl isocyanate (g), (115 mg, 0.56 mmol) was added at 0 
oC and the stirring was continued for 1 h at the room temperature. After 1 h, the formed 
solid was filtered and washed with CH2Cl2 thoroughly to obtain the pure compound 11g 
in 220 mg, 77% yield. Mp: 213–215 oC; [α]D25 = – 76.9 (c = 0.5 in CHCl3); 1H NMR 
(300 MHz, CDCl3):   2.91–2.99 (m, 2H), 3.74 (s, 3H), 3.78 (s, 6H), 4.20–4.26 (m, 1H), 
4.30–4.48 (m, 2H), 5.40–5.46 (m, 1H), 5.90 (d, 2H, J = 12.2 Hz), 6.30 (s, 2H), 6.71 (s, 
1H), 7.30 (d, 2H, J = 8.43 Hz), 7.50 (s, 1H), 7.62 (d, 2H, J = 8.43 Hz), 7.90 (d, 2H, J = 
8.10 Hz), 8.41 (s, 1H). 13C NMR (75 MHz, CDCl3):   41.1, 43.3, 47.7, 55.6, 60.6, 68.5, 
101.2, 107.6, 109.0, 109.5, 116.4, 116.9, 119.4, 121.9, 124.1, 125.6, 126.2, 128.2, 129.1, 
131.9, 131.6, 134.4, 137.2, 137.5, 137.9,  142.4, 146.9, 151.8, 152.3, 166.1, 174.3. MS 
(ESI): m/z 788 [M+H]+. 
6.10.N1-((5S,5aS,8aR,9R)-8-oxo-9-(3,4,5-trimethoxyphenyl)-5,5a,6,8,8a,9-hexahydro 
[1,3]dioxolo[4',5':4,5]benzo[f]isobenzofuran-5-yl)-4-(((4-methoxyanilino)carbonyl) 
amino)benzamide (11h): To a solution of N1-((5S,5aS,8aR,9R)-8-oxo-9-(3,4,5-
trimethoxyphenyl)-5,5a,6,8,8a,9-hexahydro[1,3]dioxolo [4',5':4,5]benzo[f]isobenzofuran-
5-yl)-4-aminobenzamide (10), (200 mg, 0.37 mmol) in dry CH2Cl2 (10 mL), 4-
methoxyphenyl-1-isocyanate (h), (84 mg, 0.56 mmol) was added at 0 oC and the stirring 
was continued for another 1 h at the room temperature. After 1 h, the formed solid was 
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filtered and washed with CH2Cl2 thoroughly obtained the pure compound 11h in 180 mg, 
75% yield. Mp: 164–67 oC; [α]D25 = – 35.7 (c = 0.5 in CHCl3); 1H NMR (200 MHz, 
CDCl3):   3.41–3.48 (m, 2H), 3.73 (s, 12H), 4.30 (t, 1H, J =  8.05 Hz), 4.50–4.59 (m, 2H), 
5.50–5.58 (m, 1H), 5.90 (d, 2H, J = 1.79 Hz), 6.30 (s, 2H), 6.50 (s, 1H), 6.70 (t, 2H, J = 
8.05, 8.95 Hz), 6.80 (s, 1H), 7.50 (d, 2H, J = 8.95 Hz), 7.80 (d, 2H, J = 8.95 Hz), 8.20 (d, 
2H, J = 7.10 Hz), 8.30 (d, 2H, J = 7.10 Hz). 13C NMR (75 MHz, CDCl3):  40.8, 43.3, 
47.3, 55.5, 57.0, 60.0, 68.4, 100.8, 107.5, 108.7, 109.1, 115.8, 116.3, 116.9, 123.5, 123.9, 
125.9, 128.4, 128.9, 129.3, 131.6, 134.8, 137.1, 137.8, 142.6, 146.7, 151.7, 152.0, 158.2, 
166.6, 174.5. MS (ESI): m/z 682 [M+H]+. 
6.11.N1-((5S,5aS,8aR,9R)-8-oxo-9-(3,4,5-trimethoxyphenyl)-5,5a,6,8,8a,9-hexahydro 
[1,3]dioxolo[4',5':4,5]benzo[f]isobenzofuran-5-yl)-4-(((1-naphthylamino)carbonyl) 
amino)benzamide (11i): To a solution of N1-((5S,5aS,8aR,9R)-8-oxo-9-(3,4,5-
trimethoxyphenyl)-5,5a,6,8,8a,9-hexahydro[1,3]dioxolo [4',5':4,5]benzo[f]isobenzofuran-
5-yl)-4-aminobenzamide (10), (200 mg, 0.37 mmol) in dry CH2Cl2 (10 mL), naphthalene-
1-isocyanate (i), (95 mg, 0.56 mmol) was added at 0 oC and the stirring was continued for 
1 h at the room temperature. After 1 h, the formed solid was filtered and washed with 
CH2Cl2 thoroughly to obtain the pure compound 11i in 180 mg, 83% yield. Mp: 170–174 
oC; [α]D25 = – 69.8 (c = 0.5 in CHCl3); 1H NMR (300 MHz, CDCl3):   3.23–3.29 (m, 2H), 
3.61 (s, 3H), 3.70 (s, 6H), 4.10 (t, 1H, J = 7.93 Hz), 4.30–4.38 (m, 2H), 5.20–5.27 (m, 
1H), 5.70 (d, 2H, J = 3.96 Hz), 6.00 (s, 2H), 6.40 (s, 1H), 6.61 (s, 1H), 7.30–7.59 (m, 
7H), 7.61–7.78 (m, 2H), 7.91 (d, 1H, J = 7.93 Hz), 8.31 (d, 1H, J = 9.32 Hz). 13C NMR 
(75 MHz, CDCl3):   40.9, 43.4, 47.3, 55.5, 60.1, 68.3, 100.7, 107.4, 108.8, 109.2, 110.8, 
116.1, 116.7, 120.1, 122.6, 123.7, 125.1, 125.7, 125.8, 126.6, 127.5, 128.3, 129.2, 129.6, 
131.4, 134.6, 134.4, 137.7, 137.7, 142.1, 142.4, 146.5, 151.9, 152.3, 166.6, 174.4. MS 
(ESI): m/z 702 [M+H]+. 
 6.12.N1-((5S,5aS,8aR,9R)-8-oxo-9-(3,4,5-trimethoxyphenyl)-5,5a,6,8,8a,9-hexahydro 
[1,3]dioxolo[4',5':4,5]benzo[f]isobenzofuran-5-yl)-4-((((2-furylmethyl)amino)    
carbonyl)amino)benzamide (11j): To a solution of N1-((5S,5aS,8aR,9R)-8-oxo-9-
(3,4,5-trimethoxyphenyl)-5,5a,6,8,8a,9-hexahydro[1,3]dioxolo 
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[4',5':4,5]benzo[f]isobenzofuran-5-yl)-4-aminobenzamide (10), (200 mg, 0.37 mmol) in 
dry CH2Cl2 (10 mL), furfuryl isocyanate (j), (0.48 mL, 0.56 mmol) was added at 0 oC and 
the stirring was continued for another 1 h at the room temperature. After 1 h, the formed 
solid was filtered and washed with CH2Cl2 thoroughly obtained the pure compound 11j 
in 210 mg, 79% yield. Mp: 210–213 oC; 1[α]D25 = – 29.7 (c = 0.5 in CHCl3); 1H NMR 
(400 MHz, CDCl3):   3.40–3.45 (m, 2H), 3.70 (s, 3H), 3.73 (s, 6H), 4.25 (d, 1H, J = 5.85 
Hz), 4.29 (d, 2H, J = 5.12 Hz), 4.50–4.65 (m, 2H), 5.51–5.58 (m, 1H), 6.20 (d, 1H, J = 
2.92 Hz), 6.30 (s, 2H), 6.51 (s, 1H), 6.70 (s, 1H), 7.21 (d, 2H, J = 7.35 Hz), 7.50 (d, 2H, J 
= 7.35 Hz), 7.80 (d, 1H, J = 8.04 Hz), 8.10 (d, 1H, J = 8.04 Hz). 13C NMR (75 MHz, 
CDCl3):   40.1, 40.8, 43.1, 47.2, 55.6, 60.2, 68.5, 100.7, 107.1, 107.6, 108.9, 109.4, 
111.2, 116.2, 116.9, 123.9, 126.3, 128.2, 129.0, 131.4, 134.3, 137.1, 137.7, 143.2, 142.5, 
146.8, 149.7, 151.9, 152.3, 166.4, 174.1. MS (ESI): m/z 655 [M+H]+. 
 6.13.N1-((5S,5aS,8aR,9R)-8-oxo-9-(3,4,5-trimethoxyphenyl)-5,5a,6,8,8a,9-hexahydro 
[1,3]dioxolo[4',5':4,5]benzo[f]isobenzofuran-5-yl)-4-((((2-chloroethyl)amino)     
carbonyl)amino)benzamide (11k): To a solution of N1-((5S,5aS,8aR,9R)-8-oxo-9-
(3,4,5-trimethoxyphenyl)-5,5a,6,8,8a,9-hexahydro[1,3]dioxolo 
[4',5':4,5]benzo[f]isobenzofuran-5-yl)-4-aminobenzamide (10), (200 mg, 0.37 mmol) in 
dry CH2Cl2 (10 mL), 2-chloroethyl isocyanate (k), (0.07 mL, 0.56 mmol) was added at 0 
oC and the stirring was continued for another 1 h at the room temperature. After 1 h, the 
formed solid was filtered and washed with CH2Cl2 thoroughly to obtain the pure 
compound 11k in 160 mg, 66% yield. Mp: 201–203 oC; 1[α]D25 = – 86.7 (c = 0.5 in 
CHCl3); 1H NMR (400 MHz, CDCl3):   3.44–3.56 (m, 2H), 3.59–3.65 (m, 2H), 3.72 (s, 
3H), 3.73 (s, 6H), 3.78–3.87 (m, 3H), 4.31–4.39 (m, 1H), 4.54 (d, 1H, J = 3.91 Hz), 5.44–
5.50 (m, 1H), 5.95 (s, 2H), 6.29 (s, 2H), 6.49 (s, 1H), 6.83 (s, 1H), 7.43 (d, 2H, J = 7.83 
Hz), 7.80 (d, 2H, J = 7.83 Hz). 13C NMR (75 MHz, CDCl3):   41.0, 42.1, 43.3, 43.8, 47.2, 
55.4, 59.8, 68.5, 100.9, 107.7, 109.0, 109.4, 116.1, 117.2, 124.0, 125.8, 128.0, 129.0, 
131.1, 134.5, 137.2, 137.7, 142.5, 146.7, 151.8, 152.4, 166.3, 174.3. MS (ESI): m/z 661 
[M+Na]+. 
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 6.14.N1-((5S,5aS,8aR,9R)-8-oxo-9-(3,4,5-trimethoxyphenyl)-5,5a,6,8,8a,9-hexahydro 
[1,3]dioxolo[4',5':4,5]benzo[f]isobenzofuran-5-yl)-4-((((2-bromoethyl)amino) 
carbonyl)amino)benzamide (11l): To a solution of N1-((5S,5aS,8aR,9R)-8-oxo-9-(3,4,5-
trimethoxyphenyl)-5,5a,6,8,8a,9-hexahydro[1,3]dioxolo [4',5':4,5]benzo[f]isobenzofuran-
5-yl)-4-aminobenzamide (10), (200 mg, 0.37 mmol) in dry CH2Cl2 (10 mL), 2-
bromoethyl isocyanate (l), (0.13 mL, 0.56 mmol) was added at 0 oC and the stirring was 
continued for another 1 h at the room temperature. After 1 h, the formed solid was 
filtered and washed with CH2Cl2 thoroughly to obtain the pure compound 11l in 170 mg, 
70% yield. Mp: 212–214 oC; 1[α]D25 = – 76.2 (c = 0.5 in CHCl3); 1H NMR (300 MHz, 
CDCl3):   2.96–3.10 (m, 2H), 3.54–3.59 (m, 2H), 3.62 (s, 3H), 3.66 (s, 6H), 3.69–3.79 
(m, 3H), 3.83–3.92 (m, 1H), 4.36 (t, 1H, J = 7.55, 7.17 Hz), 4.57 (d, 1H, J = 4.91 Hz), 
5.40–5.49 (m, 1H), 5.99 (d, 2H, J = 4.91 Hz), 6.32 (s, 2H), 6.57 (s, 1H), 6.83 (s, 1H), 
7.46 (d, 2H, J = 8.49 Hz), 7.81 (d, 2H, J = 8.49 Hz). 13C NMR (75 MHz, CDCl3):    40.1, 
40.8, 43.2, 47.3, 50.2, 55.5, 60.0, 68.4, 100.8, 107.5, 108.7, 109.1, 116.0, 116.8, 123.8, 
125.9, 128.0, 129.3, 131.6, 134.7, 137.3,  137.8,  142.6, 146.7, 151.8, 152.2, 166.5, 174.3. 
MS (ESI): m/z 705 [M+Na]+. 
 7. Materials and Methods 
7.1. Procedure of the SRB-assay:  
The synthesized compounds 11a–l have been evaluated for their in vitro cytotoxicity 
in human cancer cell lines. A protocol of 48 h continuous drug exposure has been used 
and a sulforhodamine B (SRB) protein assay has been used to estimate cell viability or 
growth. The cell lines were grown in DMEM medium containing 10% fetal bovine serum 
and 2 mM L-glutamine and were inoculated into 96 well microtiter plates in 90 microliter 
at plating densities depending on the doubling time of individual cell lines. The microtiter 
plates were incubated at 37 oC, 5% CO2, 95% air, and 100% relative humidity for 24 h 
prior to addition of experimental drugs. Aliquots of 10 microliter of the drug dilutions 
were added to the appropriate microtiter wells already containing 90 microliter of cells, 
sulting in the required final drug concentrations. For each compound four concentrations 
(0.1, 1, 10 and 100 µM) were evaluated and done in triplicate wells. Plates were 
incubated further for 48 h and assay was terminated by the addition of 50 microliter of 
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cold trichloro acetic acid (TCA) (final concentration, 10% TCA) and incubated for 60 
min at 4 oC. The plates were washed five times with tap water and air dried. 
Sulforhodamine B (SRB) solution (50 mL) at 0.4% (w/v) in 1% acetic acid was added to 
each of the cells, and plates were incubated for 20 min at room temperature. The residual 
dye was removed by washing five times with 1% acetic acid. The plates were air dried. 
Bound stain was subsequently eluted with 10 mM trizma base, and the absorbance was 
read on an ELISA plate reader at a wavelength of 540 nm with 690 nm reference 
wavelengths. Percent growth was calculated on a plate by plate basis for test wells 
relative to control wells. The above determinations were repeated three times. Percentage 
growth was expressed as the (ratio of average absorbance of the test well to the average 
absorbance of the control wells) *100. Growth inhibition of 50% (GI50) was calculated 
from [(Ti - Tz)/(C - Tz)] *100 ¼ 50, which is the drug concentration resulting in a 50% 
reduction in the net protein increase (as measured by SRB staining) in control cells 
during the drug incubation. Where, Tz ¼ Optical density at time zero, OD of control ¼ C, 
and OD of test growth in the presence of drug ¼ Ti. 
7.2. Cell culture:  
Human colon (Colo-205) and breast (MDA-MB-231) carcinoma cells were 
purchased from American Type Culture collection Centre (ATCC). Dulbecco’s modified 
Eagle’s medium (DMEM) (Invitrogen), supplemented with 2 mM glutamax (Invitrogen), 
10% fetal calf serum and 100 U/ml Penicillin and 100  mg/ml streptomycin sulfate 
(Sigma) was used as growth media for MDA-MB-231 cells. RPMI medium 
supplemented with 10% FCS with appropriate antibiotics (Penicillin, Streptomycin and 
Kanamycin) was used for growing Colo-205 cells. These cell lines were maintained at 37 
oC in a humidified atmosphere containing 5% CO2 in the incubator.  
7.3. MTT assay: 
Individual wells of a 96-well tissue culture micro titer plate were inoculated with 100 
µL of complete medium containing 1 104 cells. The plates were incubated at 37 °C in a 
humidified 5% CO2 incubator for 18 h prior to the experiment. After medium removal, 
100 µL of fresh medium containing the test compounds 11a, 11h, 11k, 11l and etoposide 
(Eto) at different concentrations such as 0.5, 1, 2 and 4 µM were added to each well and 
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incubated at 37 °C for 24 h. Then the medium was discarded and replaced with 10 µL 
MTT dye. Plates were incubated at 37 ˚C for 2 h. The resulting formazan crystals were 
solubilized in 100 µL extraction buffer. The optical density (O.D) was read at 570 nm 
with micro plate reader (Multi-mode Varioskan Instrument-Themo Scientific). The 
percentage of DMSO in the medium never exceeded 0.25%. 
7.4. Trypan blue exclusion test of cell viability 
This method is used to determine the number of viable cells present in cell 
suspension. This method is based on the principle that live cells possess intact cell 
membranes that excludes trypan blue; whereas dead cells are not capable of excluding 
trypan blue. Here viable cells show a clear cytoplasm where as non viable cells show blue 
colour cytoplasm. Compounds were treated for 24 h time period. After compound 
treatment (11a, 11h, 11k, 11l and etoposide (Eto) at 1, 2 and 4 µM concentrations, the 
cells were trypsinized and the dead and viable cells were counted. Each sample was 
assayed for triplicates. In this assay 10 µl of 0.4% solution of trypan blue was added to 
100 µl of cells. Once after mixing the sample was loaded on to haemocytometer and 
examined immediately. The percentage of dead cells was calculated. 
7.5. ATP content bioluminescence assay:  
The content of intracellular ATP was measured by bioluminescent assay on the basis 
of the measurement of the light output of the luciferin-luciferase reaction. The luciferin-
luciferase was purchased as a kit from Promega Company. Colo-205 cells were treated 
with concentration of 2 µM for 24 h, then cells were harvested and lysed after treatment 
with ice cold RIPA buffer, and cell extracts were obtained. After centrifugation at 12,000 
rpm for 2 minutes at 4 oC to remove cell debris, we collected supernatants for ATP 
measurement. The amount of ATP was determined by the ATP monitoring kit. 
7.6. Cell cycle analysis:  
For flow cytometric analysis of DNA content, 5 105 Colo-205 cells in exponential 
growth were treated at a concentration of 2 µM of 11a, 11h, 11k, 11l and etoposide (Eto) 
for 24 h.  After the incubation period, the cells were collected, centrifuged and fixed with 
ice-cold 70% ethanol at 4 oC for 30 min. Then the cells were incubated with 1 mg /ml 
  
19 
 
RNAase A solution (Sigma) at 37 oC for 30 min followed by staining with 250 µL of 
DNA staining solution [10 mg of Propidium Iodide (PI), 0.1 mg of trisodium citrate, and 
0.03 mL of Triton X-100 were dissolved in 100 mL of sterile MilliQ water at room 
temperature for 30 min in the dark]. The DNA contents of 20,000 events were measured 
by flow cytometer (DAKO CYTOMATION, Beckman Coulter, and Brea, CA). 
Histograms were analyzed using Summit Software. 
7.7. DNA topoisomerase-IIα inhibition assay:  
The mixture of 200 ng of super coiled pBR322 plasmid DNA and 4 units of human 
DNA topoisomerase-IIα (Sigma, USA) was incubated with the compounds [11a-11l and 
etoposide (Eto)] in the assay buffer (10 mM Tris–HCl (pH 7.9) containing 50 mM NaCl, 
5 mM MgCl2, 1 mM EDTA, 1 mM ATP, and 15 µg/mL bovine serum albumin) for 30 
min at 30 oC. The reaction in a final volume of 20 µL was terminated by the addition of 3 
µL of 7 mM EDTA. Reaction products were analyzed on a 1% Agarose gel at 60V for 1 
h with a running buffer of TAE. Gels were stained for 30 min in an aqueous solution of 
ethidium bromide (0.5 µg/mL). DNA bands were visualized by transillumination with 
UV light. 
7.8. DNA topoisomerase-I inhibition assay: 
The activity of DNA topoisomerase-I was determined by assessing the relaxation of 
supercoiled DNA pBR322. The mixture of 500 ng of plasmid pBR322 DNA and 0.4 units 
of recombinant human DNA topoisomerase-I (TopoGEN INC., USA) was incubated 
without and with the synthesized compounds (11a-11l) at 37 0C for 30 min in the 
relaxation buffer (10 mM Tris–HCl (pH 7.9), 150 mM NaCl, 0.1% bovine serum 
albumin, 1 mM spermidine, 5% glycerol). The reaction in the final volume of 10 µL was 
terminated by adding 2.5µ L of the stop solution containing 5% sarcosyl, 0.0025% 
bromophenol blue, and 25% glycerol. DNA samples were then electrophoresed on a 1% 
agarose gel.  
 
7.9. Caspase-3 assay:  
The caspase-3 fluorescent assay kit (Clonetech, CA) was applied to evaluate the 
caspase-3 activity, using the procedures provided by the manufacturer. Colo-205 cells 
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were treated with compounds 11a, 11h, 11k, 11l and etoposide (Eto) at 2 µM 
concentration for 24h.  Cell lysates were added to the 2X reaction buffer containing DTT 
and caspase substrate was added and incubation was carried out at 37  C for 1 h. 
Readings were taken at excitation wavelength 400 nm and emission wavelength 505 nm. 
7.10. Protein extraction and Western blot analysis:  
Colo-205 human colon cancer cells were seeded in 60 mm dishes and were allowed to 
grow to attain 80% confluency for 24 h. Compounds (11a, 11h, 11k, 11l and etoposide 
(Eto)) were added to the culture media for a final concentration of 2 µM, and the cells 
were incubated with compounds for 24 h. After 24 h, total cell lysates from cultured colo-
205 cells were obtained by lysing the cells in ice-cold RIPA buffer (1X PBS, 1% NP- 40, 
0.5% sodium deoxycholate, and 0.1% SDS) containing100 mg/mL PMSF, 5 mg/mL 
aprotinin, 5 mg/ml Leupeptin, 5 mg/mL Pepstatin, and 100 mg/mL NaF. After 
centrifugation at12000 rpm (8064 g) for 10 min, protein in the supernatant was quantified 
by the Bradford method (BioRad) using a Multimode VarioSkan instrument (Thermo 
Scientific); 50 µg proteins per lane was loaded on a 12% SDS-polyacrylamide gel. After 
electrophoresis, the protein was transferred to a polyvinylidine difluoride (PVDF) 
membrane (Amersham Biosciences). The membrane was blocked at room temperature 
for 2 h in TBS containing 0.1% Tween 20 (TBST) with 5% blocking powder (Santa Cruz 
Biotechnology). The membrane was washed with TBST for 5 min and then primary 
antibody was added and incubated at 4 oC overnight. Active caspase-3 and  -actin were 
purchased from Imgenex Corporation (San Diego, CA, USA). Membranes were washed 
three times with TBST for 15 min, and the blots were visualized with chemiluminescent 
reagent (Thermo Scientific). X-ray films were developed and fixed using solutions from 
Kodak. 
7.11. Hoechst nuclear staining:  
Colo-205 cells were seeded on cover slips, treated with compounds 11a and etoposide 
(Eto) for 24 h, washed with PBS and fixed with 4% Para formaldehyde for 15 min at 
room temperature. Fixed cells were incubated in PBS (pH7.4) containing DNAse-free 
RNase (Sigma) for 30 min at 37 oC and stained with Hoechst. Nuclear morphology of the 
cells was observed under confocal microscope. 
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Figure 1. Representative chemical structures of bioactive podophyllotoxin (1), etoposide 
(2), teniposide (3), NK611 (4), GL-331(5) and sorafenib (6). 
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Table 1. In vitro cytotoxic activity a(GI50  M) of 4β-[4’-(1-(aryl)ureido)benzamide] 
podophyllotoxin conjugates (11a–l) 
Compound bZr-75-1 bMCF7 cKB cGurav cDWD dColo 205 eA-549 eHop62 fSiHa gA-2780 
11a 0.13 ± 0.01 0.11±0.001 NA 1.97±0.15 0.10±0.002 0.01±0.005 2.14±0.219 0.17±0.02 NA 2.20± 
11b 2.90± 0.15 2.6±0.29 NA 2.01±0.11 2.30±0.19 2.60±0.3 NA 2.5±0.17 NA 2.8±0.57 
11c NA 0.15±0.012 2.8±0.25 NA NA NA NA NA NA NA 
11d 2.40±0.14 0.12±0.004 2.5±0.011 NA 0.1±0.002 NA 1.40±0.125 2.6±0.31 2.9±0.13 2.1±0.15 
11e 2.9±0.31 0.12±0.03 2.01±0.25 NA 2.61±0.15 2.52±0.39 1.5±0.42 2.71±0.66 NA NA 
11f 2.91±0.22 0.15±0.004 2.31±0.17 2.7±0.21 1.6±0.13 NA NA NA NA NA 
11g 2.22±0.12 2.7±0.1 2.6±0.15 NA NA NA 2.98±0.61 NA NA 2.3±0.39 
11h 0.18±0.03 1.1±0.055 2.31±0.4 0.24±0.17 1.7±0.16 0.02±0.001 1.50±0.22 0.12±0.014 NA 1.35±0.04 
11i 2±0.11 0.11±0.007 NA 2.90±0.17 NA 2.23±0.41 2.01±0.30 NA 2.3±0.09 2.22±0.37 
11j 2.6±0.15 2.9±0.22 1.93±0.01 NA 2.5±0.33 2.34±0.35 2.62±0.15 NA NA 2.3±0.09 
11k 2.9±0.31 0.1±0.002 0.21±0.007 0.1±0.004 1.6±0.27 0.01±0.009 1.12±0.19 0.12±0.014 NA 1.3±0.015 
11l 0.16±0.017 0.14±0.021 NA 1.85±0.27 0.17±0.02 0.01±0.031 0.1±0.027 0.1±0.002 0.21±0.03 0.14±0.01 
hEtoposide 0.2±0.015 2.11±0.024 0.31±0.051 0.51±0.09 0.62±0.014 0.13±0.017 3.08±0.135 0.80±0.19 3.11±0.11 1.31±0.27 
iADR 1.79±0.14 0.17±0.018 0.17±0.025 0.17±0.011 0.1±0.015 0.14±0.041 7.25±0.56 0.14±0.022 0.17±0.011 0.16±0.015 
a50  Growth inhibition and the values are mean of three determinations;  bbreast cancer, coral cancer,   dcolon cancer, elung cancer, fcervix cancer, govarian cancer, hEtoposide, iADR (adriamycin), NA = not active 
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Figure 2A. Colo-205 and MDA-MB-231 cells were treated with compounds 11a, 11h, 
11k, 11l and etoposide (Eto) at 0.5, 1, 2 and 4 µM concentration for 24 h. The MTT cell 
viability assay was conducted and the optical density (O.D) was observed at 570 nm. 
DMSO indicates the untreated cells.  
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Figure 2B. The number of viable cells present after 24 h was measured in compound 
treated [11a, 11h, 11k, 11l and etoposide (Eto)] Colo-205 cells. 
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Figure 2C. The effect of compounds on cellular energy (ATP) in Colo-205 cells was 
measured by luminescence based assay. Compounds at 2 µM concentration have strongly 
depleted the cellular ATP. The error bar in the graph represents the standard deviation 
(S.D) obtained from three independent experiments. ***indicate P<0.001. Con: 
represents control untreated cells. 
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Figure 3. Colo-205 cells were treated with compounds 11a, 11h, 11k, 11l and etoposide 
(Eto) at 2 µM concentration for 24 h. The cells were further processed for FACS 
analysis. Compounds 11a, 11h, 11k and 11l have shown G1 cell cycle arrest. Control 
indicates the untreated cells. 
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Eto: pBR322+ etoposide+ topoisomerase-IIα. 
11a–11l: pBR322+ compound+ topoisomerase-IIα. 
V: pBR322 alone 
 
Figure 4A. PBR322 plasmid DNA and compounds 11a–l were added at 2 µM 
concentration along with DNA topoisomerase-IIα enzyme. The buffer used for enzyme 
activity was prepared fresh using ATP, NaCl, MgCl2, EDTA, Tris pH-7.9 components. 
The reaction was performed at 37  C for 30 min. V: pBR322 DNA alone, Eto: 
PBR322+etoposide+topoisomerase-IIα, 11a-k: PBR322+compound+topoisomerase-IIα. 
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V= PBR322 alone 
T: PBR322 + topoisomerase-I 
11a–11l: PBR322+ compound+topoisomerase-I 
CPT: PBR322+ camptothecin (CPT) + topoisomerase-I 
Figure 4B. PBR322 plasmid DNA and compounds 11a–l were added at 2 µM 
concentration along with DNA topoisomerase-I enzyme. The relaxation buffer (10 mM 
Tris–HCl (pH 7.9), 150 mM NaCl, 0.1% bovine serum albumin, 1 mM spermidine, 5% 
glycerol. The reaction was performed at 37  C for 30 min. V: PBR322 DNA alone, T: 
PBR322 + topoisomerase-I, 11a–l: pBR322+ compound+ topoisomerase-I, CPT: 
PBR322+ camptothecin (CPT) + topoisomerase-I. 
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Figure 5A, 5B 
Figure 5A.The effect of compounds 11a, 11h, 11k, 11l and etoposide (Eto) on caspase-
3. Colo-205 cells were treated with compounds at 2 µM concentration for 24 h. The cell 
lysates were subjected to fluorescence based caspase-3 assay. The compounds caused 
increase of caspase-3 protein activity. Control indicates the untreated cells. *** indicate 
P<0.001, ** indicate P<0.01, * indicate P<0.05, these comparison of compound treated 
cells were made against control untreated cells. The error bar represents the standard 
deviation (S.D) obtained from three independent experiments. 
 
Figure 5B. The effect of compounds on activation of caspase-3 by Western blot analysis. 
C: Control untreated cells. Actin was used as a loading control. 
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Figure 6. Colo-205 cells were incubated with effective compound 11a from the series 
and etoposide (Eto) at 2 and 4 µM concentrations for 24 h. Compound treated cells were 
stained with Hoechst nuclear dye. Arrow depicts the fragmented DNA and blebbing 
nature. 
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Figure 7A. Compound 11a docked in ATP binding pocket of human topoisomerase-IIα, 
showing π interactions with magnesium cation and hydrogen-bonding interactions 
observed between Arg98 and carbonyl moiety along with Ser148 and Asn150 interacting 
with methoxy moiety of structure 11a. 
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Figure 7B. Molecular docking of compounds 11h, 11k and 11l in ATP binding pocket of 
human topoisomerase-IIα enzyme. 
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Figure 7C. Compound 11a docked in DNA sequence between A113 and TGP11. 
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Scheme 1. (i) Et3N, CH2Cl2, rt, 3 h; (ii) Pd/C, H2, EtOAc, rt, 12 h; (iii) R-N=C=O (a–l), 
CH2Cl2, rt, 1 h. 
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4 -[4 -(1-(Aryl)ureido)benzamide]podophyllotoxins as DNA 
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Ahmed Kamal,*a Paidakula Suresh,a M. Janaki Ramaiah,b T. Srinivasa Reddy,a,c Ravi 
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A series of new 4 -[4 -(1-(aryl)urea)benzamido]podophyllotoxin congeners (11a–l) were 
synthesized and evaluated for their in vitro anticancer activity against six human cancer 
cell lines. Among them, compounds 11a, 11h, 11k and 11l showed significant inhibitory 
activities on DNA topoisomerase I and II , strong G1 cell cycle arrest and induces 
apoptosis, and these results are supported by molecular docking studies. 
 
 
 
